Lenvamed 10mg Capsule contains Lenvatinib, a potent multi-kinase inhibitor used primarily in the treatment of certain types of cancer. Lenvatinib exerts its therapeutic effects by selectively inhibiting receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. This mechanism helps to reduce tumor growth and metastasis by blocking the signaling pathways essential for cancer cell survival and vascular development. Lenvamed is indicated for the treatment of differentiated thyroid cancer, hepatocellular carcinoma, and advanced renal cell carcinoma, either as monotherapy or in combination with other agents, depending on the specific clinical scenario. The recommended dosage is 10mg once daily, with adjustments made based on patient tolerance and adverse effects. Common side effects include hypertension, fatigue, diarrhea, decreased appetite, and proteinuria, necessitating regular monitoring of blood pressure, liver function, and renal parameters during therapy. Lenvamed should be administered under strict medical supervision, with caution advised in patients with pre-existing cardiovascular conditions or impaired hepatic function. It is contraindicated during pregnancy due to potential teratogenic effects. Overall, Lenvamed 10mg Capsule is a valuable therapeutic option in oncology, offering targeted intervention in malignancies with limited treatment alternatives.